Clinical Trial Update: A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating safety and efficacy of a PET-adapted fixed-dose nivolumab regimen with ifosfamide, carboplatin, and etoposide in relapsed/…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• N/A (ifosfamide, carboplatin, etoposide regimen) (ifosfamide, carboplatin, etoposide)
• nivolumab (nivolumab)

Snippet

Sponsor: St. Petersburg State Pavlov Medical University | Conditions: Hodgkin Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN